9 completed, 1 recruiting. 3 Phase 2, 2 Early Phase 1, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Evolus, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BoTox Into the Sternocleidomastoid Muscles (SCM) prabotulinumtoxinA-xvfs - Neck Muscle Issue | Phase 4 | Recruiting | Boston Medical Center | 30 | 2025-05-14 | 2026-08-31 |
| Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo) - Skin Aging, Skin Wrinkling | Phase 1 | Completed | Kalpna Kay Durairaj, MD, FACS | 20 | 2024-09-03 | 2025-10-21 |
| Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA - Rhytides | Early Phase 1 | Completed | Lupo Center for Aesthetic and General Dermatology | 10 | 2023-05-01 | 2024-03-13 |
| Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines prabotulinumtoxinA - Glabellar Frown Lines | Completed | Evolus, Inc. | 756 | 2023-03-15 | 2026-06-30 | |
| Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA - Glabellar Frown Lines | Phase 2 | Completed | Evolus, Inc. | 154 | 2022-03-30 | 2024-09-04 |
| Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD prabotulinumtoxinA - Glabellar Frown Lines | Early Phase 1 | Completed | Clinical Testing of Beverly Hills | 30 | 2021-12-16 | 2024-02-06 |
| Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 DWP-450 (Botulinum purified neurotoxin, Type A) - Glabellar Frown Lines | Phase 2 | Completed | Evolus, Inc. | 570 | 2015-05-01 | 2019-04-24 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001 Botulinum toxin, Type A, 0.9% sterile, unpreserved saline - Glabellar Frown Lines | Phase 3 | Completed | Evolus, Inc. | 330 | 2015-01-01 | 2019-03-27 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 Botulinum toxin, Type A, 0.9% sterile, unpreserved saline - Glabellar Frown Lines | Phase 3 | Completed | Evolus, Inc. | 324 | 2015-01-01 | 2019-03-27 |
| Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines Botulinum purified neurotoxin, Type A - Glabellar Frown Lines | Phase 2 | Completed | Evolus, Inc. | 352 | 2014-08-01 | 2019-04-24 |
prabotulinumtoxin A (6) · Botulinum Toxins, Type A (4) · DWP450 (4) · Injections (3) · Saline Solution (1) · incobotulinumtoxinA (1)
United States (9) · Germany (1)
Rui Avelar, MD (5) · Jeffrey Spiegel, MD (1) · John Joseph, MD (1) · Kalpna K Durairaj, MD (1) · Rui Avelar (1)